Periocular Eczema Management

Introduction to Periocular Eczema

• Periocular eczema is a condition that requires careful management due to its sensitive location, with the British Journal of Dermatology recommending tacrolimus 0.1% ointment as the first-line treatment for eczema involving the skin underneath the eye due to its efficacy and safety profile in this sensitive area 1

Treatment Recommendations

• The British Journal of Dermatology recommends tacrolimus 0.1% ointment as the first-line treatment for periocular eczema, with a highly effective response rate of 89% when applied once daily to the affected area for 2-4 weeks 1
• Regular application of emollients is recommended to maintain skin barrier function, with fragrance-free, oil-in-water creams or ointments suggested, and alcohol-containing lotions or gels avoided, as recommended by the BMJ and the Annals of Oncology 2, 3
• Oral non-sedating antihistamines, such as cetirizine or loratadine, may be considered for pruritus, as suggested by the Annals of Oncology 3
• Preservative-free artificial tears may be used if tear film instability is present in patients with dry eyes, as recommended by Ophthalmology 4
• The American Academy of Dermatology recommends considering oral antibiotics, such as doxycycline 100mg twice daily or minocycline 50mg twice daily, for 6 weeks if infection is present in patients with worsening eczema despite appropriate therapy 5
• Patients with eczema should avoid potential triggers, including harsh soaps and cleansers, hot water, excessive sun exposure, and alcohol-based products, and use SPF 15+ sunscreen to prevent further irritation, as recommended by the American Academy of Dermatology 5

Treatment Approach by Grade of Condition

Topical Corticosteroid Use

7

• For patients with eczema who have failed moderate potency topical steroid treatment, a short-term trial of a higher potency topical corticosteroid should be considered, followed by topical calcineurin inhibitors if steroids remain ineffective, as recommended by the American Academy of Dermatology 8

Systemic Therapies

• Short-term oral systemic steroids are suggested for severe flares, but not recommended for long-term maintenance due to side effects, and can be used to bridge to other systemic therapies, as recommended by The Annals of Oncology and The Journal of the American Academy of Dermatology 3, 9
• For severe dermatitis (covering >30% BSA with significant symptoms), consider systemic corticosteroids (prednisone 0.5-1 mg/kg/day) and obtain same-day dermatology consultation, as recommended by the Journal for ImmunoTherapy of Cancer 6
• Alitretinoin (10-30mg daily) is particularly effective for hyperkeratotic hand eczema, and atopic dermatitis may respond to dupilumab if severe, according to The American Academy of Dermatology 10, 11, 12, 13

Patient Education and Adherence

• Patient education should include proper application technique and addressing adherence issues, such as "steroid phobia", as recommended by the American Academy of Dermatology 8
• Treatment duration should be adequate, with 1-4 weeks of intensive therapy, and consideration of the impact of eczema on quality of life, as recommended by the American Academy of Dermatology 8
• Undertreatment due to "steroid phobia" can be addressed by educating patients about proper use of medications, as suggested by the BMJ 2

Special Considerations

• Patients with a history of ocular herpes simplex virus should avoid using tacrolimus, as advised by the British Journal of Dermatology 1
• For children, the British Journal of Dermatology recommends using tacrolimus 0.03% ointment instead of 0.1% 1
• Cyclosporine and azathioprine are recommended for steroid-resistant chronic hand dermatitis, and discontinuing all topical steroids immediately is recommended in cases of suspected steroid allergy, switching to alternative non-steroid treatments, such as topical calcineurin inhibitors and moisturizers with urea 5-10%, as recommended by The British Journal of Dermatology 14, 13, 5
• Biopsy is indicated when diagnosis remains unclear despite clinical assessment, particularly if an autoimmune condition is suspected, as suggested by The American Academy of Dermatology and The American College of Rheumatology 12, 13